{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1222.1","upperLimit":"2184.1","value":"1633.8"},{"groupId":"OG001","lowerLimit":"1281.6","upperLimit":"2328.6","value":"1727.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Inflammatory cytokines (i.e., interleukin 6 \\[IL-6\\], soluble tumor necrosis factor receptor 1 \\[sTNF-R1\\], and tumor necrosis factor alpha \\[TNF-alpha\\]) that have been associated with fatigue during treatment for gastrointestinal cancer and influenced by yoga practice will be measured using high-sensitivity Quantikine immunoassay kits.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients participate in YST consisting of four 30 minute in-person yoga sessions at weeks 2, 4, 6, and 8 that instructs skills to enhance mindfulness and promote relaxation, through instruction of awareness, movement, breathing practices, and meditation.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nQuestionnaire Administration: Ancillary studies\n\nDaily Survey Administration: Ancillary studies\n\nYoga Skills Training: The YST intervention consists of four 30 minute in-person sessions that instructs skills to enhance mindfulness and promote relaxation. Participants will also be encouraged to practice daily at home.\n\nActigraphy Assessment: Ancillary studies","id":"OG000","title":"Group I (Yoga Skills Training)"},{"description":"Patients participate in four 30 minute in-person sessions of supportive conversation at weeks 2, 4, 6, 8.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nQuestionnaire Administration: Ancillary studies\n\nDaily Survey Administration: Ancillary studies\n\nAttention Control: The AC intervention consists of four 30 minute in-person sessions of supportive conversation. In addition, the interventionist will recommend that the patients write brief diary entries daily at home.\n\nActigraphy Assessment: Ancillary studies","id":"OG001","title":"Group II (Attention Control)"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"At 2 weeks after start of intervention","title":"Soluble Tumor Necrosis Factor Receptor 1 [sTNF-R1] Measured Using High-sensitivity Quantikine Immunoassay Kits","type":"SECONDARY","unitOfMeasure":"pg/ml"}